Annual ReportSee All
Application noteSee All
Our new application note outlines our established development and characterisation process for Affimer binders to four of the leading therapeutic antibodies- Trastuzumab, Rituximab, Adalimumab and Ipilimumab- for use as PK assay reagents.
Our new application note details Covance’s validation to regulatory standards of an anti-idiotypic Affimer binder to Trastuzumab as part of a bioanalytical assay.
Our new study highlights the development and validation of trastuzumab specific anti-idiotypic Affimer binders within a pharmacokinetic assay.
General MeetingsSee All
Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces that at the Annual General Meeting held earlier
Interim AnnouncementsSee All
Interim Results Analyst Presentation 2016
Investor infoSee All
Avacta's Chief Executive Officer Alastair Smith talks Proactive Investors' Andrew Scott through the latest developments across the business.
This 2 page document contains a company overview, details of Avacta's strategy and information on the investment proposition. It also contains some key informaiton on financials, the management team and key contacts.
An analysis of Avacta's unaudited preliminary results for the year ending 31 July 2017 by Turner Pope.
Poster produced by Amy Reeves, Covance Laboratories Ltd, Harrogate, UK about how they used Affimer technology for detecting and quantifying the breast cancer drug Trastuzumab.
Preliminary AnnouncementSee All
Please note: This file is an audio / video webcast and requires the WebEx ARF player to playback the recording. Download ARF player here.
Preliminary Results for the Year Ended 31 July 2015.
Presentation given by Avacta CEO Alastair Smith in February 2018, providing a review of progress against the objectives set in 2015 that were outlined at its Capital Markets Day, which took place on 7 February 2018 for financial analysts and institutional investors.
Published PaperSee All
Antibodies are indispensable tools in biomedical research, but their size, complexity, and sometimes lack of reproducibility created a need for the development of alternative binders to overcome these limitations.
Optical super‐resolution techniques allow fluorescence imaging below the classical diffraction limit of light. From a technology standpoint of view, recent methods are approaching molecular‐scale spatial resolution.
Imaging the actin cytoskeleton in cells uses a wide range of approaches. Typically, a fluorescent derivative of the small cyclic peptide phalloidin is used to image F-actin in fixed cells. Lifeact and F-tractin are popular for imaging the cytoskeleton in live cells.
Research NoteSee All
In this free webinar, Avacta's Senior Application Scientist Dr Geoff Platt presents data on Affimer proteins - next-generation affinity scaffolds with potential applications as novel biotherapeutics and renewable research and diagnostic tools.
In this free webinar, scientists from leading CRO, Covance, validated the use of Affimer reagents as critical assay reagents in a regulated pharmacokinetic assay.
This webinar features a presentation by Avacta Life Sciences' Chief Technology Officer Dr Matt Johnson. In it, he discusses using Affimer technology to inhibit PD-L1, an immune check point protein expressed by tumor cells to trick T-cells into not destroying them.
White paperSee All
Affmer proteins are recombinant affinity reagents that exhibit high affinity and high specificity binding across a range of reaction conditions.
New white paper examines a range of alternatives to antibodies This paper reviews the main applications of affnity binders and the requirements placed on them according to application.
This case study outlines Affimer technology for the generation of cancer immune checkpoint inhibitors, to demonstrate the rapid identification of a number of biotherapeutic candidate molecules.